Flow cytometric analysis of Human HLA-DR expression on Human peripheral blood cells. Human peripheral blood cells were stained with Brilliant Violet 421™ Mouse Anti-Human CD19 Antibody and either FITC IgG2b, κ Isotype Control (left panel) or SDT FITC Mouse Anti-Human HLA-DR Antibody (right panel) at 5 μl/test. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | HLA-DR |
| Location | Lysosome, Endosome, Cell membrane, Endoplasmic reticulum, Synapse |
| Accession | P01903 |
| Clone Number | TU36 |
| Antibody Type | Mouse mAb |
| Isotype Control | S0B1579 |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human peripheral blood cells |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
HLA-DR is a subtype of the human leukocyte antigen (HLA) complex, specifically classified as a class II molecule, and is encoded by genes located on chromosome 6. It plays a crucial role in the immune system by presenting peptide antigens to CD4+ T cells, which subsequently trigger adaptive immune responses, including the activation of B cells and the production of antibodies. HLA-DR is primarily expressed on antigen-presenting cells such as macrophages, dendritic cells, and B cells, and its expression levels can indicate the degree of immune system activation. This molecule is also significant in clinical settings, as it is associated with various autoimmune diseases (e.g., rheumatoid arthritis linked to HLA-DR4) and is a key factor in determining the success of organ transplants. Additionally, HLA-DR has been studied in the context of cancer immunotherapy, where its expression on tumor cells can influence the effectiveness of immune-mediated tumor suppression.
Picture
Picture
FC
